Ekaterina A. Fastova

Ekaterina A. Fastova

Auto-generated profile, based on publicly available information

Ekaterina A. Fastova

National Medical Research Center for Hematology

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2021 in Oncohematology
Verified
Journal Article
Open access
PDF file
MBM. O. Bagova
M. O. Bagova
AMAminat Umaraskhabovna Magomedova
Aminat Umaraskhabovna Magomedova
SKS. K. Kravchenko
S. K. Kravchenko
YMYa. K. Mangasarova
Ya. K. Mangasarova
OMO. V. Margolin
O. V. Margolin
VSV. G. Savchenko
V. G. Savchenko
Background. Diffuse large B-cell lymphoma (DLBCL) is one of the most common and aggressive tumors of the lymphatic system. Despite the frequency of occurrence, there is no single algorithm for treating DLBCL patients with poor prognostic factors. R-CHOP therapy does not allow achieving long-term complete remissions. Therefore, there is a need for second and subsequent lines of therapy. At the same time, the effectiveness of each subsequent therapy is low, while the toxicity increases. There are many randomized trials of the DLBCL treatment; however, there are only a few studies on the comparative efficacy of high-dose chemotherapy at the induction stage.The objective of the study: the evaluation of the effectiveness and toxicity of R-DA-EPOCH and R-mNHL-BFM-90 induction courses in DLBCL patients with poor prognostic factors in a randomized multicenter clinical trial “DLBCL-2015”.Materials and methods. As of April 2021, 140 patients from 13 medical institutions in Russia were included in the randomized multicenter clinical trial DLBCL-2015. As part of this study, the analysis of pharmacoeconomic factors and effectiveness of combined immunochemotherapy R-DA-EPOCH and R-mNHL-BFM-90 in patients with prognostically unfavorable DLBCL had been performed. From January 2018 to April 2021, this study included 41 patients (21 men, 20 women) with a newly diagnosed DLBCL, with 2 or more factors of an unfavorable prognosis, who were treated at the National Research Center for Hematology of the Ministry of Health of the Russian Federation. Of these, 21 patients received R-DA-EPOCH, and 20, R-mNHL-BFM-90 therapy. Median age for R-DA-EPOCH patients was 52 years (range 30–64); for R-mNHL-BFM-90 patients, 40 years (range 18–60). All patients had high-intermediate and high risk according to the international (IPI) and age-adjusted (aaIPI) prognostic index. The primary protocol endpoints were rates of complete remission, partial remission, disease progression, and hematologic and non-hematologic toxicity. Side effects were assessed in accordance with the Common Terminology Criteria for Adverse Events (CTCAE) criteria.Results. By the end of 6 induction courses, the frequency of achieving complete remission on R-mNHL-BFM-90 therapy was 100 % (20/20) compared to R-DA-EPOCH, where the complete remission rate was 71.4 % (15/21) (p = 0.0097), partial remission and progression were 14.3 % (n = 3) and 14.3 % (n = 3), respectively. Hematological toxicity on therapy according to the R-mNHL-BFM-90 scheme exceeded that on R-DA-EPOCH in terms of myelotoxic agranulocytosis (p = 0.0536), anemia (p = 0.0464) and thrombocytopenia grade III–IV (p = 0.0206). When assessing non-hematological toxicity at the compared courses, no statistically significant differences were noted, all complications occurred with the same frequency.Conclusion. Treatment according to the R-mNHL-BFM-90 protocol is highly effective as first line therapy in high-intermediate and high-risk DLBCL patients. The hematologic toxicity is higher on the R-mNHL-BFM-90 than on the R-DA-EPOCH therapy, but it is acceptable. Non-hematological toxicity in both programs is comparable.

1 October 2024 in Clinical oncohematology
Verified
Journal Article
Open access
PDF file
YMYana Konstantinovna Mangasarova
Yana Konstantinovna Mangasarova
RAR. R. Abdurashidova
R. R. Abdurashidova
AMAminat Umaraskhabovna Magomedova
Aminat Umaraskhabovna Magomedova
OMO. V. Margolin
O. V. Margolin
ENE. S. Nesterova
E. S. Nesterova
EZE. E. Zvonkov
E. E. Zvonkov
BACKGROUND. Up to now, neither the optimal treatment regimen for primary mediastinal large B-cell lymphoma (PMBCL), nor poor/favorable prognostic factors for risk stratification at the disease onset have been found. The prognosis of PMBCL is determined by the depth of metabolic response by the time of treatment completion, which underlies a response-adapted strategy. Besides, PMBCL is an aggressive tumor occurring more commonly in young women of reproductive age, which requires the development of treatment strategy during pregnancy. AIM. To assess the efficacy of the response-adapted strategy in PMBCL treatment based on the DA-EPOCH-R program in remission induction with drug dose escalation and without subsequent radiotherapy, if a complete metabolic response is reported by PET-CT. MATERIALS & METHODS. This prospective single-center clinical trial enrolled 154 patients in the period from November 2012 to March 2023. The median age of the patients was 34 years (range 19–68 years). There were 51 (33.1 %) men and 103 (66.9 %) women, 11 of whom were at various gestational ages of pregnancy. RESULTS. The response-adapted treatment was completed in all 154 patients. Overall response was 93.5 % (144/154), complete remission was 78.6 % (121/154), and partial remission was 14.9 % (23/154). Progression was reported in 6.5 % (10/154) of patients. With a follow-up of 60 months, the overall, disease-free, progression-free, and event-free survival rates were 93 %, 98 %, 92 %, and 76 %, respectively. The median was not reached. Prior to chemotherapy, 11 pregnant women aged 21–37 (median 29 years) had been assessed. By the time of PMBCL diagnosis, the gestational age of them varied from 9 to 37 weeks (median 26 weeks). Immunochemotherapy was administered to 9 women during pregnancy. At the gestational age of 27–38 weeks (median 34 weeks) delivery was reported in 10 patients who gave birth to 11 children. The children showed no malformations. All women with PMBCL diagnosed during pregnancy and all their children had been followed-up by the time of this publication. CONCLUSION. The response-adapted strategy of PMBCL treatment with the DA-EPOCH-R regimen and drug dose escalation showed a high immediate and long-term efficacy as well as tolerable toxicity, which provided ground for the decision against radiotherapy, if a complete metabolic response was reported by PET-CT. The results of this trial establish the main goal of treating aggressive lymphomas during pregnancy which is saving of two lives. Delivery of newborns without malformations despite immunochemotherapy justifies the use of the DA-EPOCH-R program at the gestational age > 12 weeks.

11 November 2024 in Journal of Modern Oncology
Verified
Journal Article
Open access
PDF file
ENEkaterina Nesterova
Ekaterina Nesterova
JMJana K. Mangasarova
Jana K. Mangasarova
MBMadina O. Bagova
Madina O. Bagova
EFEkaterina A. Fastova
Ekaterina A. Fastova
AMAminat U. Magomedova
Aminat U. Magomedova
ТАТеляшов Максим Александрович
Теляшов Максим Александрович
Aim. To evaluate the effectiveness of autologous hematopoietic stem cell (HSC) mobilization with empegfilgrastim in patients with lymphoproliferative diseases (LPDs) and to identify prognostic factors affecting the effectiveness of mobilization. Materials and methods. The paper analyzes the effectiveness of HSC mobilization with Extimia® by JSC "BIOCAD" (INN: empegfilgrastim) in patients with LPDs. The study included 89 patients with LPDs (Hodgkin's lymphoma, B- and T-cell lymphomas, plasma cell tumors) who were treated in 5 research centers of the Russian Federation (in Moscow and St. Petersburg). The median age of patients was 39 (18–67) years. In 26 (29%) patients, HSC mobilization was performed "in a stable state of hematopoiesis" using only pegylated granulocyte colony-stimulating factor (PEG-G-CSF), and in 63 (71%) patients after chemotherapy (CT). Empegfilgrastim was administered as a single dose of 7.5 mg subcutaneously in two regimens: 24 hours after the end of CT or at a random time. Results. Two groups of patients were identified, analyzed, and compared: those with ineffective (n=23, 26%) and effective (n=66, 74%) HSC mobilization. Univariate and multivariate statistical analyses (binary logistic regression and multiple bidirectional binary logistic regression, respectively) were sequentially performed to determine the factors associated with ineffective mobilization. In a one-factor analysis, we studied the sex, age, diagnosis, bone/bone marrow involvement, the number of previous CT lines, the status of the disease (remission/no remission), the history of radiation therapy, the time interval from the administration of empegfilgrastim to the decision to perform leukapheresis, the mode of granulocytopoiesis stimulation ("in a stable state of hematopoiesis" or after CT), the leukocyte and platelet counts. The subsequent multifactorial analysis of the two selected parameters (diagnosis and time interval from drug administration to the decision to perform leukapheresis) showed the following statistically significant risk factors for ineffective mobilization: T-cell lymphoma; T-cell lymphoma versus other (combination) diagnoses (B-cell lymphoma, Hodgkin's lymphoma and plasma cell tumor): p=0.046, Wald test, odds ratio 4.18 (95% confidence interval 0.96–19.4). The time interval from the administration of empegfilgrastim to the first leukapheresis in the effective mobilization group depended on the diagnosis. The longest period was observed in patients with plasma cell tumors and the shortest in those with T-cell lymphomas: 10 (4–10) vs 5.5 (4–6) [p=0.01, Kruskal–Wallis test]. Empegfilgrastim proved equally effective for HSC mobilization both "on stable hematopoiesis" and after CT. Conclusion. The results of the first multicenter experience with Extimia® by JSC "BIOCAD" (INN: empegfilgrastim) to mobilize autologous HSCs in LPD patients demonstrate its high efficacy with a favorable safety and tolerability profile: 74% (66/89) successful mobilizations after a single administration of a fixed dose of the drug.

28 September 2020 in Bulletin of Experimental Biology and Medicine
Verified
Journal Article
Closed access
PDF file
EFE. A. Fastova
E. A. Fastova
AMA. U. Magomedova
A. U. Magomedova
SKS. K. Kravchenko
S. K. Kravchenko
NPNataliya Petinati
Nataliya Petinati
NSN. V. Sats
N. V. Sats
VSV. G. Savchenko
V. G. Savchenko

19 November 2021 in Journal of Modern Oncology
Verified
Journal Article
Open access
PDF file
LGLiliya G. Gorenkova
Liliya G. Gorenkova
IBIrena E. Belousova
Irena E. Belousova
SKSergei K. Kravchenko
Sergei K. Kravchenko
AKAlla Mikhailovna Kovrigina
Alla Mikhailovna Kovrigina
YSYulia Sidorova
Yulia Sidorova
ШВШнейдер Татьяна Владимировна
Шнейдер Татьяна Владимировна
Background. Primary cutaneous T-cell lymphomas are rare heterogeneous group of lymphoproliferative diseases characterized by primarily involving skin and subcutaneous adipose tissue. Half of these cases are mycosis fungoides (MF), for about 25% are cutaneous CD30+ lymphoproliferative diseases (CD30+ LPD): primary cutaneous anaplastic large cell lymphoma (pcALCL) and lymphomatoid papulosis (LyP). During the initiating treatment of patients with MF and Szary syndrome (SS), carried out on the territory of the Russian Federation, for about 30% of patients are resistant to various therapeutic effects, especially in the later stages. The problem of the treatment of CD30+ LPD is extracutaneous dissemination in case of pcALCL, steadily relapsing course of LyP without symptom-free intervals. These characteristics of the therapy of cutaneous lymphomas demand for the need to search for new treatment options. Brentuximab vedotin, according to the results of the international randomized ALCANZA trial, has shown high efficiency in the treatment of cutaneous T-cell lymphoproliferative diseases. Aim. To evaluate the efficacy of brentuximab vedotin application in patients with cutaneous T-cell lymphomas in adverse risk group received at least one line of systemic therapy. Materials and methods. The study included 21 patients: 16 men and 5 women. The diagnosis of MF was verified in 8 patients, SS in 5 patients, cutaneous CD30+ LPD in 6 patients (5 patients pcALCL, 1 patient LyP) and a primary cutaneous peripheral T-cell lymphoma, unspecified in 2 patients. The diagnosis of cutaneous T-cell lymphoma was verified on the basis of the anamnesis of the disease, on the character of cutaneous lesions, on histological, immunohistochemical and in some cases on molecular genetic testing of the biopted sample of the skin (the assessment of T-cell receptor gene rearrangement). Results. The late stages of the disease were diagnosed in 12 of 13 patients with MF/SS. Extracutaneous lesions were diagnosed in 57% of cases. The median of prior lines therapy was 3 (18 variants of treatment). The overall response to the treatment was achieved in 91% of cases (in 19 of 21 patients): the complete remission was obtained in 53% of cases, very good partial remission in 31% of cases and partial remission in 16% of cases. The progression of the disease was determined in 2 patients (after the first and fourth cycles). Some patients with partial remission as a result of therapy using brentuximab vedotin had the additional therapy (radiation therapy, interferon , the cycles of systemic therapy) and these acts gave an option of achieving deeper antitumor response. The early relapse was diagnosed in 2 of 19 patients who had responded to the treatment. The treatment tolerability was acceptable, and the toxicity did not exceed the already known one described in earlier studies. Thus, the stable overall antitumor response had been persisting in 89% of patients (the median of the observation was 10 months). Conclusion. The use of targeted therapy with brentuximab vedotin gave an option of achieving high treatment results in group of patients with advanced stages of the disease and inefficiency of several lines of therapy.

11 June 2025 in Russian Medicine
Verified
Journal Article
Open access
NKNatalia M. Khelminskaya
Natalia M. Khelminskaya
ECEkaterina Vadimovna Cherepanova
Ekaterina Vadimovna Cherepanova
VFValentina N. Fedorova
Valentina N. Fedorova
APAlexandra V. Posadskaya
Alexandra V. Posadskaya
EFEkaterina E. Faustova
Ekaterina E. Faustova
КИКравец Виктор Иванович
Кравец Виктор Иванович
Background: Despite significant advances in the treatment of patients with inflammatory maxillofacial diseases, there have been cases of secondary cicatricial deformities in the face and neck area in patients with purulent and inflammatory diseases. The share of such cases in maxillofacial surgery hospitals is 77.5%–89.3% of total patients. The medical acoustic test used to diagnose abnormal scarring in patients with purulent and inflammatory maxillofacial and neck diseases allows for localizing the identified lesions based on anisotropic parameters, which is certainly relevant for treatment and prevention of soft tissue deformities in healthcare practices. Aim: To substantiate the relevance of acoustic screening to improve diagnosis and prevention of secondary soft tissue deformities of the face and neck in patients with maxillofacial diseases. Methods: The clinical study included 30 patients undergoing inpatient and outpatient observation in the maxillofacial surgery department and rehabilitation office of a multidisciplinary clinical hospital. The patients were divided into two groups. Group 1 comprised 15 patients with maxillofacial phlegmon of various origin, location, and localization of the affected tissue plane; group 2 comprised 15 patients after scheduled surgeries without signs of inflammation. The study included physical examination; interviews to identify complaints, anamnesis morbi, and anamnesis vitae; investigations; radiological imaging and functional tests, acoustometry, and examination by a physician and anesthesiologist. Integumentary tissues were evaluated using an acoustometer on postoperative days 1, 14, and 60. The mechanical skin properties were assessed around the wound by measuring the velocity Vp in orthogonal directions, including Vу along the vertical axis of the face and Vх along the horizontal axis of the face. Based on the measured values, the anisotropy coefficient K = Vу/Vх was calculated. Vn was simultaneously assessed in a similar region on the healthy side. Results: Group 1 velocity changes during the study were more than 2.5 times higher than those in group 2. The study proved that the velocity measured by an acoustic device in patients with purulent and inflammatory maxillofacial diseases is 2.5 times higher than the wave velocity in patients without signs of inflammation. Conclusion: Changes in acoustic parameters recorded at different stages of wound healing in maxillofacial surgery objectively reflect the regeneration progress and allow for studying the type of abnormal scarring. Early diagnosis helps prevent the abnormal scarring and determine the medical, physical, or radiation therapy strategies.